β-adrenergic blockade attenuates cardiac dysfunction and myofibrillar remodelling in congestive heart failure

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 3, 2011, Pages 545-554

  Machackova, Jarmila ^a   Sanganalmath, Santosh K ^a   Elimban, Vijayan ^a   Dhalla, Naranjan S ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Atenolol; Myofibrillar ATPase; Myosin heavy chain; Propranolol; Troponin I

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM MAGNESIUM); ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; MYOSIN HEAVY CHAIN; PROPRANOLOL; TROPONIN I;

ANIMAL; ARTICLE; DOSE RESPONSE; DRUG EFFECT; ECHOCARDIOGRAPHY; GENE EXPRESSION; GENETICS; HEART; HEART FAILURE; HEART INFARCTION; HEART MUSCLE; HEART VENTRICLE REMODELING; HEMODYNAMICS; MALE; METABOLISM; NORTHERN BLOTTING; PATHOPHYSIOLOGY; PHOSPHORYLATION; RAT; SPRAGUE DAWLEY RAT;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ATENOLOL; BLOTTING, NORTHERN; CA(2+) MG(2+)-ATPASE; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY; GENE EXPRESSION; HEART; HEART FAILURE; HEMODYNAMICS; MALE; MYOCARDIAL INFARCTION; MYOCARDIUM; MYOSIN HEAVY CHAINS; PHOSPHORYLATION; PROPRANOLOL; RATS; RATS, SPRAGUE-DAWLEY; TROPONIN I; VENTRICULAR REMODELING;

ANIMALIA; RATTUS;

EID: 79953293542     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01015.x     Document Type: Article

References (59)

1. Adameova A, Abdellatif Y, Dhalla NS. Role of the excessive amounts of circulating catecholamines and glucocorticoids in stress-induced heart disease. Can J Physiol Pharmacol. 2009; 87: 493-514.
2. Sabbah HN. The cellular and physiologic effects of β-blockers in heart failure. Clin Cardiol. 1999; 22: V16-20.
3. Brophy JM, Joseph L, Rouleau JL. β-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med. 2001; 134: 550-60.
4. Heidenreich PA, Lee TT, Massia BM. Effect of β-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol. 1997; 30: 27-34.
5. Bristow MR. β-adrenergic receptor blockade in chronic heart failure. Circulation. 2000; 101: 558-69.
6. Dhalla NS, Dent MR, Tappia PS, et al Subcellular remodeling as a viable target for the treatment of congestive heart failure. J Cardiovasc Pharmacol Therapeut. 2006; 11: 31-45.
7. Dhalla NS, Saini-Chohan HK, Rodriguez-Leyva D, et al Subcellular remodeling may induce cardiac dysfunction in congestive heart failure. Cardiovasc Res. 2009; 81: 429-38.
8. 2+ content in isolated failing and nonfailing human myocardium. Circ Res. 1999; 85: 38-46.
9. Scheuer J, Bhan AK. Cardiac contractile proteins. Adenosine triphosphatase activity and physiological function. Circ Res. 1979; 45: 1-12.
10. Schwartz K, Lecarpentier Y, Martin JL, et al Myosin isoenzymic distribution correlates with speed of myocardial contraction. J Mol Cell Cardiol. 1981; 13: 1071-5.
11. Machackova J, Barta J, Dhalla NS. Molecular defects in cardiac myofibrillar proteins due to thyroid hormone imbalance and diabetes. Can J Physiol Pharmacol. 2005; 83: 1071-91.
12. Machackova J, Barta J, Dhalla NS. Myofibrillar remodeling in cardiac hypertrophy, heart failure and cardiomyopathies. Can J Cardiol. 2006; 22: 953-68.
13. Effron MB, Bhatnagar GM, Spurgeon HA, et al Changes in myosin isoenzymes, ATPase activity, and contraction duration in rat cardiac muscle with aging can be modulated by thyroxine. Circ Res. 1987; 60: 238-45.
14. Cummins P, Lambert SJ. Myosin transitions in the bovine and human heart. A developmental and anatomical study of heavy and light chain subunits in the atrium and ventricle. Circ Res. 1986; 58: 846-58.
15. Miyata S, Minobe W, Bristow MR, et al Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circ Res. 2000; 86: 386-90.
16. Sanganalmath SK, Barta J, Takeda N, et al Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myocardial infarction. Can J Physiol Pharmacol. 2008; 86: 180-9.
17. Dixon IM, Lee SL, Dhalla NS. Nitrendipine binding in congestive heart failure due to myocardial infarction. Circ Res. 1990; 66: 782-8.
18. Schiller NB, Shah PM, Crawford M, et al Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989; 2: 358-67.
19. Wang J, Liu X, Ren B, et al Modification of myosin gene expression by imidapril in failing heart due to myocardial infarction. J Mol Cell Cardiol. 2002; 34: 847-57.
20. Sanganalmath SK, Babick AP, Barta J, et al Antiplatelet therapy attenuates subcellular remodelling in congestive heart failure. J Cell Mol Med. 2008; 12: 1728-38.
21. Tso JY, Sun XH, Kao TH, et al Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: genomic complexity and molecular evolution of the gene. Nucleic Acids Res. 1985; 13: 2485-502.
22. Liu X, Takeda N, Dhalla NS. Troponin I phosphorylation in heart homogenate from diabetic rat. Biochim Biophys Acta. 1996; 1316: 78-84.
23. Hulsmann M, Sturm B, Pacher R, et al Long-term effect of atenolol on ejection fraction, symptoms, and exercise variables in patients with advanced left ventricular dysfunction. Heart Lung Transplant. 2001; 20: 1174-80.
24. Mittioli AV, Modena MG, Fantini G, et al Atenolol in dilated cardiomyopathy: a clinical instrumental study. Cardiovasc Drugs Ther. 1990; 4: 505-7.
25. Lampert R, Ickovics JR, Viscoli CJ, et al Effects of propranolol on recovery of heart rate variability following acute myocardial infarction and relation to outcome in the β-blocker Heart Attack Trial. Am J Cardiol. 2003; 91: 137-42.
26. Maia ER, Villacorta H, Subietta CG, et al Use of propranolol in heart failure patients: safety, tolerability, and effects on left ventricular function. Rev Port Cardiol. 2001; 20: 383-99.
27. 1-selective and nonselective β-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. Circulation. 1996; 94: 353-8.
28. Zaca V, Rastogi S, Mishra S, et al Atenolol is inferior to metoprolol in improving left ventricular function and preventing ventricular remodeling in dogs with heart failure. Cardiology. 2009; 112: 294-302.
29. 2+-dependent ATP consumption in triton X-skinned fiber preparations of human myocardium. J Pharmacol Exp Ther. 2007; 322: 222-7.
30. Gwathmey JK, Kim CS, Hajjar RJ, et al Cellular and molecular remodeling in a heart failure model treated with the β-blocker carteolol. Am J Physiol Heart Circ Physiol. 1999; 276: H1678-90.
31. Schmidt U, del Monte F, Miyamoto MI, et al Restoration of diastolic function in senescent rat hearts through adenoviral gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase. Circulation. 2000; 101: 790-6.
32. Ito K, Yan X, Feng X, et al Transgenic expression of sarcoplasmic reticulum Ca(2+) atpase modifies the transition from hypertrophy to early heart failure. Circ Res. 2001; 89: 422-9.
33. Sun YL, Hu SJ, Wang LH, et al Comparison of low and high doses of carvedilol on restoration of cardiac function and calcium-handling proteins in rat failing heart. Clin Exp Pharmacol Physiol. 2005; 32: 553-60.
34. Plank DM, Yatani A, Ritsu H, et al Calcium dynamics in the failing heart: restoration by beta-adrenergic receptor blockade. Am J Physiol Heart Circ Physiol. 2003; 285: H305-15.
35. Zanchetti A, Stella A. Neural control of renin release. Clin Sci Mol Med Suppl. 1975; 2: 215s-23s.
36. Eichhorn EJ, Heesch CM, Risser RC, et al Predictors of systolic and diastolic improvement in patients with dilated cardiomyopathy treated with metoprolol. J Am Coll Cardiol. 1995; 25: 154-62.
37. Esler M, Kaye D. Measurement of sympathetic nervous system activity in heart failure: the role of norepinephrine kinetics. Heart Fail Rev. 2000; 5: 17-25.
38. Wang J, Guo X, Dhalla NS. Modification of myosin protein and gene expression in failing hearts due to myocardial infarction by enalapril or losartan. Biochim Biophys Acta. 2004; 1690: 177-84.
39. Honig CR. Depression of myosin B by catecholamine analogs: mechanism and in vivo significance. Am J Physiol. 1968; 214: 357-64.
40. Harris DE, Work SS, Wright RK, et al Smooth, cardiac and skeletal muscle myosin force and motion generation assessed by cross-bridge mechanical interactions in vitro. J Muscle Res Cell Motil. 1994; 15: 11-9.
41. Lowes BD, Minobe W, Abraham WT, et al Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest. 1997; 100: 2315-24.
42. VanBuren P, Harris DE, Alpert NR, et al Cardiac V1 and V3 myosins differ in their hydrolytic and mechanical activities in vitro. Circ Res. 1995; 77: 439-44.
43. Imamura S, Matsuoka R, Hiratsuka E, et al Adaptational changes of MHC gene expression and isozyme transition in cardiac overloading. Am J Physiol. 1991; 260: H73-9.
44. Herron TJ, McDonald KS. Small amounts of alpha-myosin heavy chain isoform expression significantly increase power output of rat cardiac myocyte fragments. Circ Res. 2002; 90: 1150-2.
45. Lowes BD, Gilbert EM, Abraham WT, et al Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med. 2002; 346: 1357-65.
46. Sen S. Myocardial response to stress in cardiac hypertrophy and heart failure: effect of antihypertensive drugs. Ann NY Acad Sci. 1999; 874: 125-33.
47. Helmke SM, Yen CY, Cios KJ, et al Simultaneous quantification of human cardiac alpha- and beta-myosin heavy chain proteins by MALDI-TOF mass spectrometry. Anal Chem. 2004; 76: 1683-9.
48. Boluyt MO, Long X, Eschenhagen T, et al Isoproterenol infusion induces alterations in expression of hypertrophy-associated genes in rat heart. Am J Physiol. 1995; 269: H638-47.
49. Bodor GS, Oakeley AE, Allen PD, et al Troponin I phosphorylation in the normal and failing adult human heart. Circulation. 1997; 96: 1495-500.
50. 2+-sensitivity of the contractile apparatus in end-stage human heart failure results from altered phosphorylation of contractile proteins. Cardiovasc Res. 2003; 57: 37-47.
51. Dohet C, al-Hillawi E, Trayer IP, et al Reconstitution of skinned cardiac fibres with human recombinant cardiac troponin-I mutants and troponin-C. FEBS Lett. 1995; 377: 131-4.
52. Mittmann K, Jaquet K, Heilmeyer LM Jr. A common motif of two adjacent phosphoserines in bovine, rabbit and human cardiac troponin I. FEBS Lett. 1990; 273: 41-5.
53. Zhang R, Zhao J, Mandveno A, et al Cardiac troponin I phosphorylation increases the rate of cardiac muscle relaxation. Circ Res. 1995; 76: 1028-35.
54. Jideama NM, Noland TA Jr, Raynor RL, et al Phosphorylation specificities of protein kinase C isozymes for bovine cardiac troponin I and troponin T and sites within these proteins and regulation of myofilament properties. J Biol Chem. 1996; 271: 23277-83.
55. Noland TA Jr, Raynor RL, Jideama NM, et al Differential regulation of cardiac actomyosin S-1 MgATPase by protein kinase C isozyme-specific phosphorylation of specific sites in cardiac troponin I and its phosphorylation site mutants. Biochemistry. 1996; 35: 14923-31.
56. 2+ sensitivity and ATPase activity in the mouse myocardium. J Physiol. 2003; 552: 845-57.
57. Gu X, Bishop SP. Increased protein kinase C and isozyme redistribution in pressure-overload cardiac hypertrophy in the rat. Circ Res. 1994; 75: 926-31.
58. 2+-sensitive isoforms in the failing human heart. Circulation. 1999; 99: 384-91.
59. Clausen T, Flatman JA. Beta 2-adrenoceptors mediate the stimulating effect of adrenaline on active electrogenic Na-K-transport in rat soleus muscle. Br J Pharmacol. 1980; 68: 749-55.